Merck To Discontinue Development Of SARS-CoV-2 Vaccine Candidates Based On Phase 1 Study Findings
Financial world news, market analysis, investment scam prevention tips and more ✔️ Learn all there is to know about the asset management industry. This magazine is crafted specifically for those who are interested in diving into the global asset management world.
(RTTNews) - Merck (MRK) has decided to discontinue development of the company's COVID-19 vaccine candidates, V590 and V591. In phase 1 clinical studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines.
To keep reading about Merck To Discontinue Development Of SARS-CoV-2 Vaccine Candidates Based On Phase 1 Study Findings, Click on the link. Seoul, Korea
http://dlvr.it/RrHsMx
http://dlvr.it/RrHsMx
Comments
Post a Comment